Abstract:Brain tumors represent a heterogeneous group of neoplasms characterized by a high degree of aggressiveness and a poor prognosis. Despite recent therapeutic advances, the treatment of brain tumors, including glioblastoma (GBM), an aggressive primary brain tumor associated with poor prognosis and resistance to therapy, remains a significant challenge. Receptor tyrosine kinases (RTKs) are critical during development and in adulthood. Dysregulation of RTKs through activating mutations and gene amplification contributes to many human cancers and provides attractive therapeutic targets for treatment. Under physiological conditions, the Met RTK, the hepatocyte growth factor/scatter factor (HGF/SF) receptor, promotes fundamental signaling cascades that modulate epithelial-to-mesenchymal transition (EMT) involved in tissue repair and embryogenesis. In cancer, increased Met activity promotes tumor growth and metastasis by providing signals for proliferation, survival, and migration/invasion. Recent clinical genomic studies have unveiled multiple mechanisms by which MET is genetically altered in GBM, including focal amplification, chromosomal rearrangements generating gene fusions, and a splicing variant mutation (exon 14 skipping, METex14del). Notably, MET overexpression contributes to chemotherapy resistance in GBM by promoting the survival of cancer stem-like cells. This is linked to distinctive Met-induced pathways, such as the upregulation of DNA repair mechanisms, which can protect tumor cells from the cytotoxic effects of chemotherapy. The development of MET-targeted therapies represents a major step forward in the treatment of brain tumours. Preclinical studies have shown that MET-targeted therapies (monoclonal antibodies or small molecule inhibitors) can suppress growth and invasion, enhancing the efficacy of conventional therapies. Early-phase clinical trials have demonstrated promising results with MET-targeted therapies in improving overall survival for patients with recurrent GBM. However, challenges remain, including the need for patient stratification, the optimization of treatment regimens, and the identification of mechanisms of resistance. This review aims to highlight the current understanding of mechanisms underlying MET dysregulation in GBM. In addition, it will focus on the ongoing preclinical and clinical assessment of therapies targeting MET dysregulation in GBM.

MET fusions and splicing variants convergently define a subgroup of glioma sensitive to MET inhibitors

Enhanced expression and phosphorylation of the MET oncoprotein by glioma-specific PTPRZ1-MET fusions.

RNA-seq of 272 Gliomas Revealed a Novel, Recurrent PTPRZ1-MET Fusion Transcript in Secondary Glioblastomas

Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor

MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas

MODL-06. Targeting c-MET in combination with radiation is effective in MET-fusion driven high-grade glioma

The PTPRZ1-MET/STAT3/ISG20 axis in glioma stem-like cells modulates tumor-associated macrophage polarization

Molecular characterization of MET fusions from a large real‐world Chinese population: A multicenter study

MET fusions are targetable genomic variants in the treatment of advanced malignancies

Unraveling the Significance of MET Focal Amplification in Lung Cancer: Integrative NGS, FISH, and IHC Investigation

A Pooled Analysis of Clinical Outcome in Driver-Gene Negative Non-Small Cell Lung Cancer Patients with MET Overexpression Treated with Gumarontinib

Glioblastomas harboring gene fusions detected by next-generation sequencing

Aberrant MET Receptor Tyrosine Kinase Signaling in Glioblastoma: Targeted Therapy and Future Directions

Biom-05. Fusion Transcriptome Landscape In Glioblastoma

Comprehensive analysis of <i>MET</i> mutations in NSCLC patients in a real-world setting

Precision Treatment Paradigm: Genomic Features and Therapeutic Implications in Mesenchymal‐epithelial Transition‐amplified Gastric Cancer

Circular RNA encoded MET variant promotes glioblastoma tumorigenesis

MET Gene Fusions in Non-Small Cell Lung Cancer (NSCLC) in the Chinese Population: A Multicenter Study.

Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer

c-Met-mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma.

Advances in the diagnosis and treatment of MET-variant digestive tract tumors